The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Growth Hormone and Pituitary Radiotherapy, But Not Serum Insulin-Like Growth Factor-I Concentrations, Predict Excess Mortality in Patients with Acromegaly
Open accessAbstract
Increased mortality in patients with acromegaly has been confirmed in a number of retrospective studies, but causative factors and relationship to serum IGF-I remain uncertain. The West Midlands Pituitary database contains details of 419 patients (241 female) with acromegaly. Serum IGF-I data from the Regional Endocrine Laboratory were available for 360 patients (86%). At diagnosis, mean age was 47 yr (range, 12-84) and mean duration of follow-up was 13 yr (0.5-48). Sixty-one percent were treated by surgery and 39% by nonsurgical means. Radiotherapy was used alone or as adjuvant therapy in 50%. All patients were registered with the Office of National Statistics to obtain information on deaths. At the date of analysis (31 December 2001), 95 of the 419 patients had died (43 males), giving a standardized mortality ratio of 1.26 [confidence interval (CI), 1.03-1.54; P = 0.046]. After controlling for age and sex, data indicated that mortality was increased in subjects with posttreatment GH levels more than 2 micro g/liter, compared with those with levels less than 2 micro g/liter [ratio of mortality rates (RR), 1.55 (range, 0.97-2.50); P = 0.068]. By contrast, a much smaller increase was observed for subjects with elevated posttreatment IGF-I levels compared with those with normal levels [RR, 1.20 (range, 0.71-2.03); P = 0.50]. Treatment with radiotherapy was associated with increased mortality [RR, 1.67 (range, 1.09-2.56); P = 0.018], with cerebrovascular disease the predominant cause of death [standardized mortality ratio, 4.42 (range, 2.71-7.22); P = 0.005]. These results confirm the increased mortality in acromegaly and suggest that reduction of GH levels to less than 2 micro g/liter is beneficial in terms of improving long-term outcome. The sole use of IGF-I as a marker for effective treatment of acromegaly is not justified by this data. This study also highlights the potential deleterious effect of radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Somatomedin Hypothesis: 2001
Le Roith, D., Bondy, C., Yakar, S., Liu, J.-L., & Butler, A. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.1.0419 · Cited by 1,257
Rajaram, S., Baylink, D. J., & Mohan, S. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0321 · Cited by 1,097
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006
Self-citationCriteria for Cure of Acromegaly: A Consensus Statement
Giustina, A. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.526 · Cited by 987
Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study1
Orme, S. M., McNally, R. J. Q., Cartwright, R. A., & Belchetz, P. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5007 · Cited by 805
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
van der Lely, A. J., Hutson, R. K., Trainer, P. J., Besser, G. M., Barkan, A. L., Katznelson, L., Klibanski, A., Herman-Bonert, V., Melmed, S., Vance, M. L., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06844-1 · Cited by 645
Self-citationLong-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1
Swearingen, B., Barker, F. G., Katznelson, L., Biller, B. M. K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P. M., & Zervas, N. T. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5222 · Cited by 586
Determinants of clinical outcome and survival in acromegaly
Rajasoorya, C., Holdaway, I. M., Wrightson, P., Scott, D. J., & Ibbertson, H. K. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03789.x · Cited by 565
Wright, A. D., Hill, D. M., Lowy, C., & Fraser, T. R. (1970) · PubMed · Cited by 529
WEISSBERGER, A. J., HO, K. K. Y., & LAZARUS, L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-2-374 · Cited by 514
EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION
ALEXANDER, L., APPLETON, D., HALL, R., ROSS, W. M., & WILKINSON, R. (1980) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1980.tb03135.x · Cited by 466
An audit of outcome of treatment in acromegaly
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068816 · Cited by 466
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly
Swearingen, B. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.10.3419 · Cited by 400
Guidelines for Acromegaly Management
Melmed, S., Casanueva, F. F., Cavagnini, F., Chanson, P., Frohman, L., Grossman, A., Ho, K., Kleinberg, D., Lamberts, S., Laws, E., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-011841 · Cited by 343
Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly
Beauregard, C., Truong, U., Hardy, J., & Serri, O. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01679.x · Cited by 300
Bevan, J. S., Atkin, S. L., Atkinson, A. B., Bouloux, P.-M., Hanna, F., Harris, P. E., James, R. A., McConnell, M., Roberts, G. A., Scanlon, M. F., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-012012 · Cited by 279
Self-citationAcromegaly and gastrointestinal cancer
Ron, E., Gridley, G., Hrubec, Z., Page, W., Arora, S., & Fraumeni, J. F. (1991) · Cancer · doi:10.1002/1097-0142(19911015)68:8<1673::aid-cncr2820680802>3.0.co;2-0 · Cited by 250
Acromegaly with Apparently Normal GH Secretion: Implications for Diagnosis and Follow-Up
Dimaraki, E. V., Jaffe, C. A., DeMott-Friberg, R., Chandler, W. F., & Barkan, A. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3537 · Cited by 235
Current Treatment Guidelines for Acromegaly1
Melmed, S., Jackson, I., Kleinberg, D., & Klibanski, A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.4995 · Cited by 210
Clark, Neylon, Raggatt, Sheppard, & Stewart (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00555.x · Cited by 207 · cited 1×
“The hypothalamopitutary-adrenal axis was deficient if the peak cortisol response to short synacthen testing was less than 530 nmol/liter (17) or less than 500 nmol/liter after an insulin stress test.”
MethodFreda, P. U., Post, K. D., Powell, J. S., & Wardlaw, S. L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.11.5266 · Cited by 201
Colao, A. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2779 · Cited by 179
The role of growth hormone/insulin-like growth factors in adipocyte differentiation
Wabitsch, M., Hauner, H., Heinze, E., & Teller, W. M. (1995) · Metabolism · doi:10.1016/0026-0495(95)90220-1 · Cited by 165
Freda, P. U. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.11.3808 · Cited by 155
Colao, A., Spinelli, L., Marzullo, P., Pivonello, R., Petretta, M., Somma, C. D., Vitale, G., Bonaduce, D., & Lombardi, G. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021099 · Cited by 154
Cerebrovascular mortality in patients with pituitary adenoma
Brada, M., Ashley, S., Ford, D., Traish, D., Burchell, L., & Rajan, B. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01570.x · Cited by 151
Current Treatment Guidelines for Acromegaly
Melmed, S. K. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.8.2646 · Cited by 120
Incidence of cerebral infarction after radiotherapy for pituitary adenoma
Flíckinger, J. C., Nelson, P. B., Taylor, F. H., & ROBINSON, A. G. (1989) · Cancer · doi:10.1002/1097-0142(19890615)63:12<2404::aid-cncr2820631205>3.0.co;2-3 · Cited by 105
Ayuk, J., Stewart, S. E., Stewart, P. M., & Sheppard, M. C. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011913 · Cited by 95
Self-citationHo, P. J., Jaffe, C. A., Friberg, R. D., Chandler, W. F., & Barkan, A. L. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.6.1403 · Cited by 52
Hypothalamic Dysfunction in "Cured" Acromegaly Is Treatment Modality Dependent
Peacey, S. R., Toogood, A. A., & Shalet, S. M. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4832 · Cited by 35
Dauncey, M. J., SHAKESPEAR, R. A., Rudd, B., et al. (1990) · Hormone and Metabolic Research · doi:10.1055/s-2007-1004898 · Cited by 33
Davis, J. R., Sheppard, M. C., SHAKESPEAR, R. A., LYNCH, S. S., & Clayton, R. N. (1986) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1986.tb00755.x · Cited by 22
Self-citationWeissberger, A. J., Ho, K. K. Y., & Lazarus, L. (1991) · Maturitas · doi:10.1016/0378-5122(91)90161-i · Cited by 5
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Melmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
A Consensus on Criteria for Cure of Acromegaly
Giustina, A., Chanson, P., Bronstein, M. D., Klibanski, A., Lamberts, S., Casanueva, F. F., Trainer, P., Ghigo, E., Ho, K., & Melmed, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2670 · Cited by 783
Guidelines for Acromegaly Management: An Update
Melmed, S., Colao, A., Barkan, A., Molitch, M., Grossman, A. B., Kleinberg, D., Clemmons, D., Chanson, P., Laws, E., Schlechte, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2421 · Cited by 764
Metadata
- Authors
- Ayuk, J., Clayton, R. N., Holder, G., Sheppard, M. C., Stewart, P. M., & Bates, A. S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-04
- Volume
- 89
- Issue
- 4
- Pages
- 1613-1617
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2002070825
- Cited by
- 343
- References
- 34
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.